CATALYST BIOMEDICA LTD has a total of 25 patent applications. Its first patent ever was published in 1999. It filed its patents most often in United Kingdom, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets biotechnology, pharmaceuticals and organic fine chemistry are SENTION INC, ZINFANDEL PHARMACEUTICALS INC and EPIDAUROS BIOTECHNOLOGIE AG.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 9 | |
#2 | WIPO (World Intellectual Property Organization) | 7 | |
#3 | Australia | 5 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Organic fine chemistry | |
#4 | Basic materials chemistry | |
#5 | Chemical engineering | |
#6 | Measurement |
# | Name | Total Patents |
---|---|---|
#1 | Carr Andrew | 10 |
#2 | Loughlin John | 10 |
#3 | Sykes Bryan | 10 |
#4 | Greenman John | 4 |
#5 | Boyle Ross William | 4 |
#6 | Sutton Jonathan Mark | 2 |
#7 | Marshall Chris | 2 |
#8 | Futreal Andy | 2 |
#9 | Wooster Richard | 2 |
#10 | Marais Richard Malcolm | 2 |
Publication | Filing date | Title |
---|---|---|
WO03060111A2 | Cancer-specific mutants of b-raf genes and uses thereof | |
GB0130796D0 | Genes | |
GB0130778D0 | Novel compounds | |
EP1294726A2 | Improvements in and relating to chromophores | |
GB0113784D0 | Novel compounds | |
GB0020351D0 | Treatment of hyperproliferative diseases | |
WO0047769A1 | Susceptibility locus for osteoarthritis | |
WO0047770A1 | Susceptibility locus for osteoarthritis | |
GB9926417D0 | Susceptibility locus | |
GB9926414D0 | Susceptibility locus | |
AU6110299A | Susceptibility locus for osteoarthritis | |
AU6110599A | Susceptibility locus for osteoarthritis | |
GB9903442D0 | Susceptibilty locus | |
GB9903441D0 | Susceptibilty locus |